Oncosia Establishes Meaningful Foothold in Türkiye: A Growing Market for Personalised Dosimetry

One year after market entry, Oncosia reports first clinical installations, new isotope qualifications, and a deepening partnership with Siemens Healthineers Türkiye.

Türkiye has firmly established itself as an outstanding growth market in nuclear medicine — characterised by a rapidly expanding base of radiopharmaceutical therapy programs, increasing availability of novel tracers, and a community of highly motivated clinicians and scientists. The high volume of both Selective Internal Radiation Therapy (SIRT/TARE) and Molecular Radiotherapy (MRT) procedures performed annually underscores the country's exceptional treatment capacity, which increasingly attracts patients from across the region seeking high-quality care.

Growth markets of this kind, however, come with specific demands: sites require expert support in qualifying clinical workflows, training staff, and establishing robust dosimetry protocols from the ground up. One year ago, at the Turkish Congress of Nuclear Medicine 2025, Oncosia announced its entry into this market with precisely this mission in mind. This year, we returned to the Annual Turkish Congress of Nuclear Medicine 2026 — and twelve months of results speak for themselves: first clinical installations, a growing network of collaborating institutions, and a clear signal that Türkiye will be among our most active markets in the years ahead. Central to this is a fact that remains unique in the Turkish market: Oncosia is the the dosimetry provider in Türkiye with Turkish-speaking application specialists and scientists on the ground, ensuring the community's needs are not just heard, but genuinely understood.

Underpinning Oncosia's clinical offering is PLANET® Dose — the voxel-based, AI-assisted dosimetry platform developed by our solution partner DOSIsoft. PLANET® Onco Dose 3.2 is a multi-radionuclide, multi-workflow platform designed to enable truly personalised patient therapy across both SIRT/TARE and MRT indications. Critically, it is the dosimetry software in Türkiye with full ÜTS registration, covering both modalities — providing Turkish institutions with the regulatory certainty they need to implement dosimetry programs at scale with confidence.

The latest version brings several clinically significant capabilities:

The application of Actinium-225 (²²⁵Ac) is expanding rapidly across sites in Türkiye, reflecting a broader global shift toward targeted alpha therapy.

A particularly significant development is Oncosia's ability to deliver targeted alpha therapy dosimetry on ²²⁵Ac-PSMA patient data, made possible through a combination of in-house advanced Monte Carlo-based image reconstruction software and optimised clinical imaging protocols developed by Oncosia's scientific team. This capability represents a meaningful validation of Oncosia's standing as an expert dosimetry vendor for clinical trials — demonstrating not only software competency, but the full scientific infrastructure required to generate reliable dosimetric data in the context of emerging therapies.

Directly following the congress, Oncosia is in the process of qualifying three sites in Türkiye for ¹⁶¹Tb imaging and dosimetry workflows, including phantom studies and calibration services. This work is being carried out as part of the TeLuNa trial — an investigator-initiated study of ¹⁶¹Tb-PSMA therapy (NCT07441837).

Oncosia acts as the central dosimetry vendor for this trial, in close collaboration with Ankara University Faculty of Medicine and its principal investigator, Prof. Çiğdem Soydal.

Importantly, the TeLuNa trial spans not only multiple sites across Türkiye, but also extends to European partner sites — positioning Oncosia at the centre of a multi-national, investigator-initiated study and further validating its role as a trusted expert vendor in the clinical trial space.

The congress featured a scientific presentation arising directly from Oncosia's first clinical installation in Türkiye, at Çukurova University:

"Time Point Selection in Two-Point Voxel Dosimetry for ¹⁷⁷Lu-DOTATATE Therapy: Which Pairing Shows the Best Agreement with Four-Point Dosimetry?" Original title: "Lu-177 DOTATATE Tedavisinde İki Noktalı Voksel Dozimetride Zaman Noktası Seçimi: Dört Noktalı Dozimetri ile En Uyumlu Eşleştirme Hangisi?"

This study investigates whether a simplified two-timepoint imaging protocol for voxel dosimetry can produce results comparable to the gold-standard four-timepoint approach in ¹⁷⁷Lu-DOTATATE therapy. By identifying the optimal pair of acquisition timepoints, the work addresses a clinically important question: how to reduce patient burden and resource requirements without compromising dosimetric accuracy — a key consideration for scaling personalised dosimetry into routine practice.

This work is a testament to the speed and quality of clinical adoption at Çukurova — reflecting not only the strength of PLANET® Dose as a platform, but the comprehensive professional services that accompanied the installation: the setup of optimised imaging protocols, phantom studies, and thorough training of clinical and physics staff. That a scientific contribution of this quality has emerged from the very first installation cycle is a result we are genuinely proud of.

We extend our deep gratitude to Assoc. Prof. Burak İsa Güney and the entire team at Çukurova University for this excellent and productive collaboration. We look forward to many more joint scientific contributions ahead.

At the congress, Oncosia co-hosted a dosimetry workshop with Siemens Healthineers Türkiye — bringing together an enthusiastic audience of medical physicists, technologists, and physicians for a focused session on personalised dosimetry with PLANET® Dose, presented alongside Siemens Healthineers Türkiye's latest innovations in SPECT and PET imaging, including the Symbia Prospecta SPECT/CT and the Biograph Trinion PET/CT. The workshop was met with exceptional engagement and underscored the strong clinical appetite for expert-supported dosimetry solutions in Türkiye.

Beyond the workshop, Oncosia was present at the Siemens Healthineers Türkiye booth throughout the congress — a visible expression of the close and productive partnership between our two organisations. We extend our sincere gratitude to the entire Siemens Healthineers Türkiye team for their outstanding collaboration, both at the congress and in the broader mission of bringing personalised dosimetry to Turkish institutions.

Türkiye is just getting started. With a solid foundation of clinical installations, qualified sites, a central role in multi-site clinical trials, and a dedicated dosimetry team on the ground, Oncosia is well-positioned for significant growth in the Turkish market. Many projects are in the pipeline — and the community's response at this congress made clear that the demand for high-quality, expertly supported dosimetry has never been stronger.

We look forward to continuing these collaborations and to everything that lies ahead.